Clinical Genomics announced the appointments of Mary Padbury and Katherine Bach Kalin to its board. Padbury who will be the chairman of the board, has done intellectual property work for Australian and multinational companies. She was most recently a partner and vice chairman of law firm Ashurst. She currently is chairman of the board for Trans-Tasman IP Attorneys.
Kalin has more than 25 years of experience as a senior executive in the healthcare and professional services industries. Most recently, she led corporate strategy at Celgene. Prior to that, she held leadership roles in marketing, sales, strategy, and new bbusiness development at Johnson & Johnson.